Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

Targeting GABAergic Hypofunction Associated with Schizophrenia: Identification of α1β2γ2GABA-A Receptor Ligands with Neuroprotective and Antipsychotic Properties.

Created on 07 Jun 2025

Authors

Barbara Mordyl, Katarzyna Szafrańska, Joanna Sniecikowska, Jakub Jonczyk, Bartłomiej Bieńko, Maria Mateos-Jimenez, Bartosz Wojdyła, Beata Gryzło, Monika Głuch-Lutwin, Agata Siwek, Tadeusz Karcz, Karolina Słoczyńska, Elżbieta Pękala, Alicja Zakrzewska-Sito, Pawel Mierzejewski, Marcin Kołaczkowski, Monika Marcinkowska

Published in

ACS chemical neuroscience. Jun 06, 2025. Epub Jun 06, 2025.

Abstract

Clinical evidence has demonstrated significant hypofunction of GABAergic neurotransmission in patients with schizophrenia, likely contributing to the onset of psychotic symptoms. These symptoms can be alleviated by α1β2γ2GABA-A receptor ligands, which have previously shown antipsychotic activity. Building on this foundation, we synthesized and characterized various derivatives of 2-phenylimidazo[1,2-a]-pyridine containing cyclic amine moieties at the amide backbone to identify potent ligands and expand the chemical space of α1β2γ2GABA-A receptor ligands. The synthesized compounds exhibited Ki values ranging from 25.0 to 7822.5 nM and positive allosteric properties at α1β2γ2GABA-A receptors. Selected compounds exhibited promising cellular permeability properties, high metabolic stability, and neuroprotective activity. A representative derivative of this series elicited antipsychotic-like properties, reversing amphetamine- and MK-801-induced hyperlocomotion without inducing sedative effects. Our findings indicate that α1β2γ2GABA-A ligands represent a promising strategy for the identification of potential antipsychotic agents with an original mechanism of action.

PMID:
40479553
Bibliographic data and abstract were imported from PubMed on 07 Jun 2025.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 18
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement